Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033115 | 0.90 | CYP2A6 (0.50) | CYP2A6CYP1A2TAAR1HTR2AHTR1D | |
| SCHEMBL15345396 | 0.85 | CYP2A6 (0.57) | CYP2A6CYP1A2TAAR1HTR2AHTR1D | |
| SCHEMBL7838287 | 0.84 | CYP2A6 (0.55) | CYP2A6CYP1A2HTR2AMTNR1AMTNR1B | |
| SCHEMBL19518945 | 0.80 | CYP2A6 (0.47) | CYP2A6CYP1A2HTR2AMTNR1AMTNR1B | |
| SCHEMBL7752840 | 0.79 | CYP2A6 (0.59) | CYP2A6CYP1A2HTR2AMTNR1AMTNR1B | |
| Ammonia Solution, Strong SCHEMBL27919153 | 0.79 | CYP1A2 (0.50) | CYP2A6CYP1A2HTR2AMTNR1A | |
| SCHEMBL19392617 | 0.79 | HTR1A (0.53) | CYP2A6CYP1A2TAAR1HTR2AHTR1D | |
| SCHEMBL17187823 | 0.79 | MPO (0.50) | CYP2A6CYP1A2TAAR1HTR2AMTNR1A | |
| SCHEMBL7103988 | 0.79 | MTNR1A (0.57) | CYP1A2TAAR1HTR2AHTR1DMTNR1A | |
| SCHEMBL17187827 | 0.79 | HTR2A (0.50) | CYP2A6TAAR1HTR2AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016931-B1 | A NOVEL PROCESS FOR THE PREPARATION OF TETRALIN AND NAPHTHALENE DERIVATIVES | PHARMATHEN SA (GR) | 2021-02-24 | — | — | EP | disclosed |
| EP-2921473-B1 | 1-CYAN-1-(7-METHOXYL-1-NAPHTYL) METHANOL ESTER COMPOUND AND PREPARATION METHOD AND USE THEREOF | JIANGXI SYNERGY PHARMACEUTICAL CO LTD (CN) | 2017-09-27 | — | — | EP | disclosed |
| US-RE46218-E1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2016-11-29 | — | — | US | disclosed |
| US-8853449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8779199-B2 | Agomelatine intermediates and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| US-20130289307-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| EP-1564202-B1 | Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these | SERVIER LAB (FR) | 2008-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | COMT, AGO2, MC5R | CYP2A6 130/4885CYP1A2 40/4885TAAR1 296/4885 |
| US-20130289307-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | CYP2A6 90/4885CYP1A2 45/4885TAAR1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.